AnaptysBio Inc

NASDAQ:ANABUnited States

May 9, 2024

Show headlines and story abstract

• Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update, from 4:15PM ET on Thursday May 09, 2024 by GlobeNewswire

  4:15PM ET on Thursday May 09, 2024 by GlobeNewswire
  Companies Mentioned: ANAB

• Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update, from 4:15PM ET on Thursday May 09, 2024 by Dow Jones

  4:15PM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: ANAB
  
  antagonist antibody (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn and X.
  
  Forward-Looking Statements
  
  This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company's clinical trials, including ANB032's Phase 2b clinical trial in atopic dermatitis and rosnilimab's Phase 2b clinical trial in rheumatoid arthritis and Phase 2 clinical trial in ulcerative colitis; the timing of IND filings for ANB033 and ANB101; the timing of a presentation of Phase 3 clinical data at a medical conference; the potential to receive any additional royalties from the GSK collaboration; the Company's ability to find a licensing partner for imsidolimab or etokimab and the timing of any such transaction; and the Company's projected cash runway. Statements including words such as "plan," "intend," "continue," "expect," or "ongoing" and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company's ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company's ability to fund development activities and achieve development goals, the company's ability to protect intellectual property and other risks and uncertainties described under the heading "Risk Factors" in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
  

• *DJ AnaptysBio 1Q Loss/Shr $1.64 >ANAB, from 4:15PM ET on Thursday May 09, 2024 by Dow Jones

  4:15PM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: ANAB

• Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP), from 4:10PM ET on Thursday May 09, 2024 by GlobeNewswire

  4:10PM ET on Thursday May 09, 2024 by GlobeNewswire
  Companies Mentioned: ANAB